Patents Examined by James H. Alstrum-Acevedo
  • SOCS1-derived peptide for use in chronic complications of diabetes
    Patent number: 10532082
    Abstract: The present invention relates to a SOCS1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the SOCS1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: January 14, 2020
    Assignees: Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma De Madrid
    Inventors: Jesús Egido De Los Rios, Carmen Gómez Guerrero, Rafael Simó Canonge, Cristina Hernández Pascual
  • Inhibitors of prototypic galectin dimerization and uses thereof
    Patent number: 10519239
    Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
  • Inhibition of MK2 in the treatment of cancer
    Patent number: 10512651
    Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 24, 2019
    Assignee: STC.UNM
    Inventor: Ellen Janine Beswick
  • Conotoxin peptide ?-CPTx-BTL01, preparation method therefor, and uses thereof
    Patent number: 10501498
    Abstract: Provided is a new conotoxin peptide ?-CPTx-bt101. The conotoxin peptide ?-CPTx-bt101 has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1, or has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1 and that is formed after substitution, addition or deletion of one or more amino acids are performed and has original functions. Also provided is polynucleotide for coding the peptide, comprising a constructed body of the polynucleotide, an expression carrier and transformed cells. A peptide preparation method and uses in the treatment of diseases related to a calcium ion channel.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: December 10, 2019
    Assignee: BGI SHENZHEN
    Inventors: Jie Liu, Zhilong Lin, Bo Wen, Ting Tong, Fen Mo, Chao Peng, Qiong Shi
  • Albumin variants
    Patent number: 10501524
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: December 10, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Uses of peptides to treat brain injury and disease
    Patent number: 10501494
    Abstract: A method of treating loss of brain function in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which A is Ala, or absent, B is Ser, Thr or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, Ile, Leu, E is Ser, Thr, Asp, Asn, F is Thr, Ser, Asn, Arg, Gln, Lys, Trp, G is Tyr, and H is Thr, Ser, Arg, Gly. All amino acids in the D peptide are the D stereoisomeric configuration. The peptide composition is administered in a therapeutically effective dose.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: December 10, 2019
    Assignee: Creative Bio-Peptides
    Inventor: Michael Ruff
  • Peptides that stimulate subcutaneous adipogenesis
    Patent number: 10494402
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
    Patent number: 10495642
    Abstract: The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases. The present invention further relates to a method for detecting breast cancer metastasis, comprising the step of detecting at least one protein that is specific for the secretome of a chondrocyte, and for methods for treating and/or preventing breast cancer metastasis in a patient in need thereof, comprising the step of administering an effective amount of at least one ligand for one protein that is specific for the secretome of a chondrocyte to said patient in need thereof.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: December 3, 2019
    Assignee: ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
    Inventors: Prasad Shastri, Jon Christensen, Xavier Lucas, Stefan Günther
  • LLP2A-bisphosphonate conjugates for osteoporosis treatment
    Patent number: 10494401
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • Oxyntomodulin analogue
    Patent number: 10479819
    Abstract: Provided is an oxyntomodulin analogue. The analogue comprises GCGR and GLP-1R dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions. The analogue can be used to prepare medication for treating hyperphagia, obesity and diabetes.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: November 19, 2019
    Assignee: JIANG, XIANXING
    Inventor: Xianxing Jiang
  • Methods for treating neurological disorders
    Patent number: 10471029
    Abstract: Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 12, 2019
    Assignee: Alzheon, Inc.
    Inventors: Martin Tolar, John A. Hey, Petr Kocis, Jeremy Yu
  • Pharmaceutical formulations and their use in the treatment of periodontal disease
    Patent number: 10471058
    Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 12, 2019
    Assignee: PERIOC LTD
    Inventors: Thomas Kissel, Ching Pong Mak
  • Homogenous antibody drug conjugates via enzymatic methods
    Patent number: 10471037
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 12, 2019
    Assignee: CSPC Dophen Corporation
    Inventors: Sean Hu, Lisha Allen
  • Cyclic peptide analogs and conjugates thereof
    Patent number: 10472395
    Abstract: Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 12, 2019
    Assignee: Sirenas LLC
    Inventors: Venkat Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Elizabeth Paige Stout, Jacob Neal Beverage, Bryan Junn Lee, Steven Bruce Cohen
  • Wound spray
    Patent number: 10471175
    Abstract: A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 12, 2019
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Matrix scaffold with antimicrobial activity
    Patent number: 10449271
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: October 22, 2019
    Assignee: Worcester Polytechnic Institute
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Dosage of a gluten peptide composition
    Patent number: 10449228
    Abstract: Provided herein are methods and compositions for treating subjects with Celiac disease.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: October 22, 2019
    Assignee: ImmusanT, Inc.
    Inventor: Robert P. Anderson
  • Method of treating prader-willi syndrome
    Patent number: 10441627
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 15, 2019
    Assignee: FERRING B.V.
    Inventors: Pascal Danglas, Michael Reidy, Paul Korner, Sudarkodi Alagarsamy
  • Bacteriocidal peptides and uses thereof
    Patent number: 10435447
    Abstract: Peptide compositions having bacteriocidal peptides are described. Also described is a method of bacterial infections using compositions comprising bacteriocidal peptides or modified peptides with structural relationships to cathelicidins.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: October 8, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: C. Cheng Kao, Xiaoyan Lin
  • Peptide
    Patent number: 10428110
    Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: October 1, 2019
    Assignee: HysensBio Co., Ltd.
    Inventors: Joohwang Park, Jihyun Lee